Alkermes
Alkermes plc is an Irish biopharmaceutical company focusing on neuroscience therapeutics for complex central nervous system and psychiatric disorders. The company develops and commercializes proprietary medicines, including Vivitrol for alcohol and opioid dependence, Aristada for schizophrenia, and Lybalvi for bipolar I disorder. Main revenue drivers stem from commercial sales of branded proprietary neuroscience therapies alongside manufacturing fees and royalty revenues from licensed partner products. Alkermes serves psychiatrists, addiction medicine specialists, hospital healthcare networks, and patients across the United States and international markets. The company maintains an established market position in central nervous system disorder therapeutics. Headquartered in Dublin, Ireland, Alkermes plc is listed on the Nasdaq Stock Market.
11 of the funds FundTelligence covers report a position in Alkermes.
- Legal name
- Alkermes PLC
- Sector
- Health Care
- Country
- Ireland
- Funds holding it
- 11
- Exposure themes
- Addiction, Mental Health, Psychiatry, Schizophrenia & Psychosis
Funds holding Alkermes
- HealthInvest Small & Mid Cap Healthcare — HealthInvest · 2.5 % (partially disclosed portfolio, September 2026)
- DNB Bioteknologi — DNB · 1.84 % (full portfolio disclosed, September 2026)
- BNP US Small Cap — BNP Paribas · 1.17 % (full portfolio disclosed, June 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.84 % (full portfolio disclosed, September 2026)
- BNP Health Care Innovators — BNP Paribas · 0.81 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.75 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.49 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.07 % (partially disclosed portfolio, June 2026)
Showing the 8 largest of 11 funds holding it.